Previous Close | 2.0300 |
Open | 2.0100 |
Bid | 1.9100 x 4000 |
Ask | 1.9900 x 4000 |
Day's Range | 1.9100 - 2.0200 |
52 Week Range | 1.8600 - 3.1500 |
Volume | |
Avg. Volume | 583,595 |
Market Cap | 321.709M |
Beta (5Y Monthly) | 2.13 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4600 |
Earnings Date | Nov 07, 2023 - Nov 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for ABUS
Arbutus (ABUS) makes a strategic decision to focus on the development of hepatitis B virus therapies while discontinuing all coronavirus and oral RNA destabilizer programs.
Progressing development of hepatitis B virus (HBV) compounds imdusiran (AB-729) and AB-101, an oral PD-L1 inhibitor Discontinuing all coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161 Extending cash runway through Q3 2025 WARMINSTER, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that tar
WARMINSTER, Pa., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference: Formal Presentation on September 12, 202